(PharmaNewsWire.Com, February 20, 2019 ) The sleep apnea devices market is dominated by a few players globally. Players in this market compete with each other to deliver superior quality therapeutic and diagnostic products for OSA (Obstructive Sleep Apnea). In 2017, the sleep apnea devices market was dominated by a few large players, namely, ResMed, Inc. (US), Koninklijke Philips (Netherlands), and Fisher & Paykel Healthcare Ltd. (New Zealand).
Product launches, product approvals, acquisitions, agreements, and contracts were the key strategies adopted by players between 2015 and 2018.
ResMed dominated the sleep apnea devices market in 2017. The company gained a major share in the sleep apnea devices market on account of its diversified product portfolio, widespread geographical presence, and focus on strategies such as innovation and expansions. The company strongly focuses on expansion into new product segments as well as geographies to gain a competitive edge in the market.
Thus, to enter the high growth market, ResMed acquired Laboratoires Narval, S.A. (France) to supply custom-made mandibular advancement devices. Additionally, in February 2016, ResMed acquired Brightree LLC (US), a provider of cloud-based software solutions for the post-acute care industry. This acquisition strengthened ResMed’s market position as well as significantly expanded its software product portfolio. ResMed also has a strong patent portfolio which helps the company maintain its leadering position in the market.
Koninklijke Philips is the second largest player in the global sleep apnea devices market. The company’s strong position in this market can be attributed to its acquisition of Respironics in 2008, a US-based established manufacturer and distributor of sleep and respiratory products. The company’s wide geographical presence and strong distribution network have also helped it to gain a significant market share. In the past three years, innovation has been the company’s core business strategy to increase its share in the global sleep apnea devices market.
This strategy is largely supported by the company’s strong R&D activities. The company invested USD 455.91 million (5.8% of its Personal Health segment sales) in R&D in 2017. The company’s rich pool of skilled R&D personnel ensures constant development and launch of technologically advanced products in the market. This further helps Philips to launch products like masks, PAP devices, and ventilators in the market.
Fisher & Paykel Healthcare accounted for the third largest share of the global sleep apnea devices market. The company strongly focuses on developing and establishing a direct sales force in major geographic markets. The company significantly invests in R&D activities to launch technologically advanced products in the market. The company’s rich pool of skilled R&D personnel ensures constant development and launch of advanced products in the market.
It invested USD 59.94 million, USD 51.29 million, and USD 53.98 million in R&D in 2017, 2016, and 2015, respectively. As a result of its strong R&D activities, the company has launched sleep apnea products like nasal pillow masks, optiflow nasal cannulas, and Airspiral tubes. The growing workforce, strong R&D, and consistent new product launches are likely to help the company gain a greater market share in the coming years.
Other players in the sleep apnea devices market include SomnoMed Ltd. (Australia), Compumedics Limited (Australia), Löwenstein Medical GmbH & Co. KG. (Germany), Whole You, Inc. (US), BMC Medical Co., Ltd. (China), Drive DeVilbiss Healthcare (US), and Braebon Medical Corporation (Canada).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
